Search results
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 1 month agoTakeda Pharmaceutical Co. Ltd. (NYSE:TAK) is the largest Japanese pharmaceutical company and holds a leading position in the global immunoglobulins...
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo Finance· 2 months agoTakeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects,...
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
The Wall Street Journal· 2 weeks agoHEALTH Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit...
Japan's Takeda slashes full-year profit forecast on drug pipeline impairments
Reuters via Yahoo News· 7 months agoTOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year...
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Reuters via Yahoo News· 9 months agoDrugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is...
Takeda pays $300M to license Protagonist drug for blood disorder
BioPharma Dive via Yahoo Finance· 4 months agoDive Brief: Protagonist Therapeutics, a biotechnology company focused on peptide drugs, is teaming...
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Zacks via Yahoo Finance· 2 years agoHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and...
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
BioPharma Dive via Yahoo Finance· 2 weeks agoThe deal — worth $100 million up front and potentially billions more later on — gives Takeda an...
Japan's Takeda Pharma to restructure after annual profit slump
Reuters via AOL· 2 weeks agoTOKYO (Reuters) -Japan's Takeda Pharmaceutical announced a restructuring on Thursday after annual...
UPDATE 2-Japan's Takeda to buy Nimbus' psoriasis drug for as much as $6 bln
Reuters via Yahoo Finance· 1 year agoTakeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments ...